Hemofil M

Hemofil M

factor viii

Manufacturer:

Takeda

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Antihemophilic factor human (Factor VIII)
Indications/Uses
Prevention & control of hemorrhagic episodes in hemophilia A. In those w/ acquired Factor VIII inhibitors not exceeding 10 Bethesda units/mL.
Dosage/Direction for Use
The expected in vivo peak antihemophilic factor level, expressed as IU/dL of plasma or % of normal, can be calculated by multiplying the dose administered per kg body wt (IU/kg) by 2 eg, a peak level of 70% is required in a 40-kg child: Dose should be 70/2 x 40 = 1,400 IU. IV infusion Early hemarthrosis or muscle/oral bleed 20-40% of normal plasma every 12-24 hr for 1-3 days. More extensive hemarthrosis, muscle bleed or hematoma 30-60% of normal plasma every 12-24 hr for ≥3 days. Life-threatening bleeds eg, head injury, throat bleed, severe abdominal pain 60-100% of normal plasma every 8-24 hr. Minor surgery (including tooth extraction) 60-80% of normal plasma single infusion w/in 1 hr. Major surgery (pre- & post-op) 80-100% of normal plasma every 8-24 hr.
Contraindications
Hypersensitivity to mouse protein.
Adverse Reactions
Nausea, fever, chills or urticaria.
MIMS Class
ATC Classification
B02BD02 - coagulation factor VIII ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.
Presentation/Packing
Form
Hemofil M powd for inj 250 IU
Packing/Price
1's
Form
Hemofil M powd for inj 500 IU
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in